Research: Compelling Valuation with Huge Growth Opportunitythis is Beacon Securities' Q1/2017 research note which while dated, gives a very good summary of CRH and how compelling the strategy is.
while margins will be reduced with the recent CMS changes, nothing else has fundamentally shifted at the company - the strategy has not changed and the growth prospects remain huge.
if anything, the reduction in CMS rates will encourage
more acquistions and consolidation of the colonoscopy space.
https://www.stockhouse.com/companies/bullboard/t.crh/crh-medical-corporation?postid=26272083&_ga=2.189465963.1925146267.1500296412-818932599.1490036674